Exalpha Biologicals, Inc.

Product Highlight

FIX&PERM Cell Fixation and Permeabilization Kit

Flow cytometric analyses with monoclonal antibodies were so far mainly restricted to cell surface molecules. Intracellular structures such as cytoplasmic or nuclear enzymes, oncoproteins, cytokines, immunoglobulins etc. were largely excluded from such studies. Also excluded from flow cytometric studies were cytoplasmic localizations of well-established membrane molecules like CD3 and CD22, which, in their cytoplasmic form, are the most reliable lineage markers in undifferentiated leukemia. With the FIX&PERM® Kit flow cytometric analysis of intracellular antigens has become as easy as surface antigen studies. The only prerequisite is the availability of suitable antibody conjugates. Most of the available monoclonal antibody conjugates can be used with the FIX&PERM® Kit, some determinants are sensitive, however, to the fixation step involved. This and the optimal fixation time have to be tested for each reagent.

News

Welcome, Peter Rutten

We are pleased to announce that Peter Rutten has now started in his role as Operations Director here at Exalpha Biologicals Inc. Peter has a Master’s of Science degree in Industrial and Organizational Psychology and this has lead him down a very business orientated career path. Peter is looking forward to working with the team at Exalpha. Peters primary focus is the customer experience and he will be working with the Laboratory team, the Quality Control team and the Order Processing team to ensure this focus is achieved. We all wish Peter well in his new role.

Exalpha Biologicals, Inc.

Progesterone receptor

  • Product Code: X1437M
  • Size: 100 µg
  • Availability: In Stock In Stock
  • Price (USD): $433

Cat #

X1437M		 Quantity:      

Data Sheet

Product Name

Progesterone receptor

Host/Source

Mouse

Clone

hPRa2 + hPRa3

Isotype

IgG

Product Type

Monoclonal Antibody

Reactivity

Human, Horse, Pig

Applications

Western Blot, Immunoprecipitation, Immunohistochemistry (Paraffin & Frozen sections), Immunofluorescense

Purification

Protein A/G Chromatography

Size

100 µg

Price (USD)

$433

Background

Equally recognizes two proteins: 116kDa (triplet) and 81kDa (singlet), identified as the hormone-binding high (B) and low (A) MW forms of human PgR. Expression of PgR has been suggested to reflect a intact estrogen regulatory machinery and therefore, predict better clinical response to endocrine therapy than ER alone. This antibody is excellent for immunohistochemical staining of formalin/paraffin tissues.

Immunogen

Hybridoma produced by the fusion of splenocytes from RBF/DN mice immunized with PgR from a human endometrial carcinoma (EnCa 101) grown in athymic mice and mouse myeloma HL-1 Friendly cells.

Positive Control

T47D or breast carcinoma

Formulation

Provided as solution in phosphate buffered saline with 0.08% sodium azide

Customer Storage

Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles

Product Image

Image Legend

Immunohistochemical staining using progesterone receptor antibody on formalin fixed, paraffin embedded human breast carcinoma.

Database Links:

SwissProtO00264Human

References

1. Satyaswaroop PG. Development of a preclinical model for hormonal therapy of human endometrial carcinomas. Annals of Medicine, 1993, 25:105-11.

2. Shyamala G; et al. Relationship between 90-kilodalton heat shock protein, estrogen receptor, and progesterone receptor in human mammary tumors. Breast Cancer Research and Treatment, 1993, 26(1):95-100.

3. Satyaswaroop PG; et al. Apparent resistance in human endometrial carcinoma during combination treatment with tamoxifen and progestin may result from desensitization following downregulation of tumor progesterone receptor. Cancer Letters, 1992, 62(2):107-14.

4. Clarke CL; et al. Direct transcriptional regulation of the progesterone receptor by retinoic acid diminishes progestin responsiveness in the breast cancer cell line T-47D. Journal of Biological Chemistry, 1991 Oct 5, 266(28):18969-75.

5. Schneider W; et al. Murine progesterone receptor exists predominantly as the 83-kilodalton 'A' form. Journal of Steroid Biochemistry and Molecular Biology, 1991, 38(3):285-91.

6. Mortel R; et al. Designing a schedule of progestin administration in the control of endometrial carcinoma growth in the nude mouse model. American Journal of Obstetrics and Gynecology, 1990, 162(4):928-34; discussion 934-6.

7. Clarke CL; et al. Progesterone receptor regulation by retinoic acid in the human breast cancer cell line T-47D. Journal of Biological Chemistry, 1990 Jul 25, 265(21):12694-700.

8. Clarke CL. Cell-specific regulation of progesterone receptor in the female reproductive system. Molecular and Cellular Endocrinology, 1990 May 7, 70(3):C29- 33.

9. Satyaswaroop PG; Mortel R. Hormonal treatment of endometrial carcinoma: an overview and new development in biology. Journal of Steroid Biochemistry and Molecular Biology, 1990, 37(6):997-1001.

10. Shyamala G; Schneider W; Schott D. Developmental regulation of murine mammary progesterone receptor gene expression. Endocrinology, 1990 Jun, 126(6):2882-9.

11. Alexander IE; Clarke CL; Shine J; Sutherland RL. Progestin inhibition of progesterone receptor gene expression in human breast cancer cells. Molecular Endocrinology, 1989 Sep, 3(9):1377-86.


12. Feil PD; Clarke CL; Satyaswaroop PG. A polyclonal antiserum against the rabbit progesterone receptor recognizes the human receptor: biochemical characterization. Cell Biochemistry and Function, 1989, 7(2):139-46.

13. Satyaswaroop PG; Zaino RJ; Mortel R. Carcinoma of the endometrium and hormonal receptors. Cancer Treatment and Research, 1989, 49:71-92.

14. Tabibzadeh SS; Satyaswaroop PG. Sex steroid receptors in lymphoid cells of human endometrium. American Journal of Clinical Pathology, 1989, 91(6):656-63.

15. Zaino RJ; Clarke CL; Feil PD; Satyaswaroop PG. Differential distribution of estrogen and progesterone receptors in rabbit uterus detected by dual immunofluorescence. Endocrinology, 1989, 125(5):2728-34.

16. Feil PD; Clarke CL; Satyaswaroop PG. Progesterone receptor structure and protease activity in primary human endometrial carcinoma. Cancer Research, 1988, 48(5):1143-7.

17. Feil PD; Clarke CL; Satyaswaroop PG. Progestin- mediated changes in progesterone receptor forms in the normal human endometrium. Endocrinology, 1988, 123(5):2506-13.

18. Zaino RJ; Clarke CL; Mortel R; Satyaswaroop PG. Heterogeneity of progesterone receptor distribution in human endometrial adenocarcinoma. Cancer Research, 1988, 48(7):1889-95.

19. Clarke CL; Feil PD; Satyaswaroop PG. Progesterone receptor regulation by 17 beta-estradiol in human endometrial carcinoma grown in nude mice. Endocrinology, 1987, 121(5):1642-8.

20. Satyaswaroop PG; Zaino R; Clarke CL; Mortel R. Nude mouse system in the study of tumor biology, treatment strategies and progesterone receptor physiology in human endometrial carcinoma. Journal of Steroid Biochemistry, 1987, 27(1-3):431-8.

21. Satyaswaroop PG; Zaino RJ; Mortel R. Steroid receptors and human endometrial carcinoma: studies in a nude mouse model. Cancer Metastasis Reviews, 1987, 6(3):223-41.

22. Clarke CL; et. al. Endocrinology, 1987, 121:1123-32.

23. Gray GO; Satyaswaroop PG. Biochem Biophys Res Comm, 1988, 157(3):1067-77.